Skip to main content

Table 2 Statistical data of study’s patients

From: Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study

  Lipiodol Lipiodol+EmboCept®S p-value
Number of patients 51 48 0.584
➢ female 13 8  
➢ male 38 40  
Age of patients (years) 63.8 63.4 0.972
Number of TACE 283 384 0.421
Presence of liver cirrhosis (%) 38 53  
Initial liver disease:
 Hepatitis B 10 19  
 Hepatitis C 23 13  
 Hepatitis B and C 6 3 0.643
 Hemochromatosis 1 2  
 Alcohol abusus 13 13  
BCLC-Stage:
 BCLC-Stage A 3 5 0.194
 BCLC-Stage B 35 56  
Child-Pugh class:
 A 9 18 0.206
 B 36 36  
Localisation in liver:
 Right lobar 22 23  
 Left lobe 3 2 0.310
 Bilobar 19 30  
Number of tumor lesions:
 Single 8 3  
 2 28 0  
 3 8 0 0.252
 4 4 0  
 Multifocal 0 48  
Tumor response:
 Partial response 11 14 0.211
 Stable disease 32 22  
 Progressive disease 8 12